PNQ 103-1
Alternative Names: PNQ 103 1Latest Information Update: 28 Jul 2024
At a glance
- Originator Advinus Therapeutics
- Developer Impetis Biosciences
- Class Antiasthmatics; Antineoplastics; Small molecules
- Mechanism of Action Adenosine A2B receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Allergic asthma; Breast cancer; Colorectal cancer; Pulmonary fibrosis
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Allergic-asthma in India (PO)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Breast-cancer in India (PO)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Colorectal-cancer in India (PO)